

Product datasheet for TL315524V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

PLA2G10 Human shRNA Lentiviral Particle (Locus ID 8399)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: PLA2G10 Human shRNA Lentiviral Particle (Locus ID 8399)

Locus ID: 8399

Synonyms: SPLA2, GXPLA2, GXSPLA2, MGC119918, MGC119919

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: PLA2G10 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001031688, NM 003561, NR 133651, NM 003561.1, NM 003561.2, BC106731, BC069539,

BC106732, BC111804, BM739473, NM 003561.3

UniProt ID: 015496

Summary: This gene encodes a member of the phospholipase A2 family of proteins. Alternative splicing

results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature enzyme. This calcium-dependent enzyme hydrolyzes glycerophospholipids to produce free fatty acids and lysophospholipids. In one example, this enzyme catalyzes the release of arachidonic acid from cell membrane

phospholipids, thus playing a role in the production of various inflammatory lipid mediators, such as prostaglandins. The encoded protein may promote the survival of breast cancer cells

through its role in lipid metabolism. [provided by RefSeq, Nov 2015]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).